Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany

Table 1 Patient characteristics before therapy

Characteristic	129 patients	%
Ages at diagnosis
Average	69.8 yr (SD: ± 11.4)
Median	71 yr (range: 38-91)
Ages at diagnose
< 75 yr	76	59% of 129
≥ 75 yr	53	41% of 129
≥ 80 yr	24	19% of 129
Gender
Male	93	72% of 129
Female	36	28% of 129
Tumour sites
Proximal	47	36% of 129
Distal	82	64% of 129
Proximal < 75 yr	34	72% of 47
Proximal ≥ 75 yr	13	28% of 47
Among whom proximal ≥ 80 yr	1	2% of 47
Distal < 75 yr	42	51% of 82
Distal ≥ 75 yr	40	49% of 82
Among whom distal ≥ 80 yr	23	28% of 82
Perioperative chemotherapy
Yes	45	35% of 129
No	84	65% of 129
Ages at perioperative chemotherapy
Median of all 45 patients	66 yr (range: 38-82)
Average of all 45 patients	65.7 yr (SD: ± 8.6)
< 75 yr	37	82% of 45
≥ 75 yr	8	18% of 45
Among whom ≥ 80 yr	1	1% of 45
Ages of patients without perioperative chemotherapy
Median of all 84 patients	75 yr (range: 44-91)
Average of all 84 patients	72 yr (SD: ± 11.9)
< 75 yr	39	46% of 84
≥ 75 yr	45	54% of 84
Among whom ≥ 80 yr	23	27% of 84

SD: Standard deviation.

Table 2 Postoperative patient characteristics

Kind of operation	129 patients	% of the 129	Number/percent with neoadjuvant chemotherapy
Subtotal resection	40	31%	4 of 40/10%
Gastrectomy	57	44%	21 of 57/37%
Expanded gastrectomy	11	9%	6 of 11/55%
Transhiatal oesophagus resection (Merendino)	3	2%	1 of 3/33%
Transthoracal oesophagus resection (with gastric endo-sleeve)	18	14%	14 of 18/78%
LAD
D1 (intraoperative M+, PC or no R0 possible)	11	8.5%
D2	118	91.5%
T
T0	7	5.4%	(ypT0 = 7)
T1	8	6.2%	(ypT1N0 = 5, pT1/N1 = 3)
T2	25	19.4%	(ypT2 = 12, pT2/N+ = 13)
T3	56	43.4%	(ypT3 = 18, pT3 = 37)
T4	33	25.6%	(ypT4 = 3, pT4 = 30)
N
N0	37	29%
N+	92	71%
M
M0	112	87%
M1	17	13%
Signet-ring cells
Yes	28	22%
No	101	78%
UICC
UICC IA	12	9.3%
UICC IB	7	5.4%
UICC IIA	21	16.3%
UICC IIB	26	20.2%
UICC IIIA	17	13.2%
UICC IIIB	14	10.9%
UICC IIIC	16	12.4%
UICC IV	16	12.4%

LAD: Lymph node dissection; UICC: Union internationale contre le cancer; T: Tumour size; N+: Positive lymph nodes; N0: Negative lymph nodes; M+: Distant metastases; M0: No distant metastases; PC: Peritoneal carcinosis.